Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

97
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
97
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

128
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
128
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

120
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
120
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

144
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
144
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

4.9K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.9K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

120
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
120

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemangiomas: Beyond the Skin.

Pediatrics in review·2026
Same author

Agminated, Eruptive Nevi in Patients With a History of Langerhans Cell Histiocytosis.

Pediatric dermatology·2025
Same author

The Burden of Pediatric Psoriasis: A Systematic Review.

American journal of clinical dermatology·2025
Same author

Oral JAK inhibitors for pediatric inflammatory skin disease.

Current opinion in pediatrics·2025
Same author

The Association of Psoriasis and Bacterial Infections in Pediatric Patients: A Retrospective Review.

Pediatric dermatology·2025
Same author

Fracture risk in adult versus pediatric patients with linear morphea of the extremity: A single center retrospective study.

JAAD international·2025
Same journal

Exosomes in Dermatology.

Skin therapy letter·2026
Same journal

Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.

Skin therapy letter·2026
Same journal

Erratum to: Deuruxolitinib for Alopecia Areata.

Skin therapy letter·2026
Same journal

Advances in the Management of Hyperhidrosis.

Skin therapy letter·2026
Same journal

Topical Ruxolitinib for the Treatment of Hidradenitis Suppurativa.

Skin therapy letter·2026
Same journal

Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis.

Skin therapy letter·2026
See all related articles

Related Experiment Video

Updated: Nov 30, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K

Pediatric Psoriasis Comorbidities

Nicole W Kittler, Kelly M Cordoro

    Skin Therapy Letter
    |November 16, 2020
    PubMed
    Summary
    This summary is machine-generated.

    Pediatric psoriasis patients may face similar comorbidity risks as adults. Routine age-based screenings, aligned with American Academy of Pediatrics guidelines, are recommended for early detection and intervention.

    Keywords:
    arthritisceliac diseasecomorbiditiesdiabetesinflammatory bowel diseasemetabolic syndromeobesitypediatricpsoriasisquality of lifeuveitis

    More Related Videos

    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
    02:28

    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

    Published on: March 1, 2024

    640
    Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
    09:32

    Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

    Published on: September 26, 2019

    7.5K

    Related Experiment Videos

    Last Updated: Nov 30, 2025

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    11:39

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

    Published on: July 11, 2013

    39.3K
    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
    02:28

    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

    Published on: March 1, 2024

    640
    Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
    09:32

    Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

    Published on: September 26, 2019

    7.5K

    Area of Science:

    • Dermatology
    • Pediatrics
    • Public Health

    Background:

    • Psoriasis affects 40% of patients in childhood/adolescence.
    • Adult psoriasis comorbidities are known, but pediatric data is limited.
    • Early detection of comorbidities in children is crucial for prevention and intervention.

    Observation:

    • A multidisciplinary panel developed consensus-based screening recommendations for pediatric psoriasis patients in 2017.
    • These guidelines align with the American Academy of Pediatrics' routine age-related screening for healthy children.
    • Screening is recommended even without overt signs or symptoms of comorbidities.

    Findings:

    • Pediatric psoriasis patients share comorbidity risks with adults.
    • Current screening guidelines are practical and align with existing pediatric care standards.
    • Collaboration between dermatologists and primary care physicians is essential for effective screening.

    Implications:

    • Establishes a framework for proactive management of pediatric psoriasis comorbidities.
    • Facilitates early intervention, potentially improving long-term health outcomes for affected children.
    • Highlights the importance of integrated care models in managing chronic childhood conditions.